Tsakok T, et al. - The researchers herein, evaluated the effect of an intensified dosing schedule of subcutaneous methotrexate in individuals having moderate to severe chronic plaque psoriasis. In this 52-week study, subcutaneous methotrexate was generally well tolerated, with no serious adverse events. The inference drawn was that subcutaneous methotrexate was favorable in individuals with psoriasis.